{
  "docId": "019dd923-622c-750b-8b9a-2a2468219173",
  "docSlug": "ce565b841c40",
  "documentTitle": "Nevro Corp. (NVRO)",
  "authorId": "58_Scorpion_Capital",
  "authorName": "Kir Kahlon",
  "documentKindSlug": "activist-deck",
  "documentKindLabel": "Activist deck",
  "sourceTypeSlug": "short_seller",
  "sourceTypeLabel": "Short seller",
  "presentationDate": "2021-01-07 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.3333334,
  "pageNumber": 186,
  "pageCount": 239,
  "prevPage": 185,
  "nextPage": 187,
  "slideType": "villain_critique",
  "function": "name_villain",
  "density": "dense",
  "nDataPoints": 2,
  "notes": "The slide uses a 'villain' framing by characterizing Nevro's technology as 'gimmicky' and 'one-size fits all' while highlighting a competitor's superior clinical outcomes.",
  "elementsJson": [
    "headline_text",
    "paragraph",
    "big_number",
    "callout_box",
    "footnote"
  ],
  "metadataConfidence": 0.95,
  "imagePath": null,
  "slideHref": "/slides/019dd923-622c-750b-8b9a-2a2468219173/186",
  "deckHref": "/decks/019dd923-622c-750b-8b9a-2a2468219173",
  "deckJsonHref": "/decks/019dd923-622c-750b-8b9a-2a2468219173.json",
  "deckAnchorHref": "/decks/019dd923-622c-750b-8b9a-2a2468219173#slide-186",
  "components": [
    {
      "bbox": null,
      "kind": "callout",
      "text": "Saluda’s approach – personalize stimulation not only by patient but second by second – is the polar opposite of and a frontal challenge to Nevro’s entire reason for existence: a gimmicky one-size fits all approach based on a fixed 10kHz frequency.",
      "attrs": null,
      "subkind": null,
      "toolName": "Visual emphasis",
      "toolSlug": "visual-emphasis",
      "confidence": null,
      "componentId": "019dd953-3f3d-76db-b348-19fb5d916de3",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.35,
        "w": 0.45,
        "x": 0.06,
        "y": 0.57
      },
      "kind": "chart",
      "text": "89.1% at 12 months; 89.5% at 24 months",
      "attrs": null,
      "subkind": "donut",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "621487a2-1568-4d1a-853a-6bab480eb816",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.35,
        "w": 0.39,
        "x": 0.55,
        "y": 0.53
      },
      "kind": "list",
      "text": "Saluda's AVALON study: Sustained Long-Term Outcomes... Conclusion: The 12-mo results from the Avalon study show the highest degree of pain relief recorded for an SCS system to date.",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "1182b1bb-02ef-47a3-a413-a5e2a390927f",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": null,
      "kind": "metric",
      "text": "pain relief rate: 89.5%",
      "attrs": null,
      "subkind": "primary",
      "toolName": "Quantification",
      "toolSlug": "quantification",
      "confidence": null,
      "componentId": "019dd953-3f3d-76db-b348-23338c0086b0",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.35,
        "w": 0.88,
        "x": 0.06,
        "y": 0.09
      },
      "kind": "paragraph",
      "text": "14. Unknown to most investors, Nevro faces an impending, disruptive competitive threat within 6 to 12 months: Saluda...",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "9df805c2-e781-4b2d-9bbf-b60e3fd836f7",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": null,
      "kind": "quote",
      "text": "Conclusion The 12-mo results from the Avalon study show the highest degree of pain relief recorded for an SCS system to date. — Avalon Study",
      "attrs": null,
      "subkind": null,
      "toolName": "Authority citation",
      "toolSlug": "authority-citation",
      "confidence": null,
      "componentId": "019dd953-3f3d-76db-b348-1d842347dbae",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.88,
        "x": 0.06,
        "y": 0.95
      },
      "kind": "source-note",
      "text": "Source: https://www.saludamedical.com; https://academic.oup.com/neurosurgery/article/87/4/E485/5727863; *per Crunchbase",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "c23caac9-18d4-4a7c-8e1f-662223e918dd",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.35,
        "x": 0.06,
        "y": 0.04
      },
      "kind": "title",
      "text": "Scorpion Capital | Nevro (NYSE: NVRO)",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "c14af553-84a8-4340-b4b0-a83afe218384",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [
    {
      "name": "antagonist-introduction",
      "slug": null,
      "matchId": "6eb97021-625f-4aa2-87c7-ee43a0a83983",
      "evidence": "Frames Nevro as a failing incumbent with a 'gimmicky' product facing a superior competitor.",
      "confidence": 0.9
    }
  ],
  "arcBeats": [],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}